Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic Acid and Bezafibrate in Primary Biliary Cholangitis
NCT04594694Phase 2Terminated
- Sponsor
- Intercept Pharmaceuticals
- Start
- Oct 2019
- Primary completion
- Oct 2025
- Modality
- Orthosteric Ligands
- Countries
- 17
01
Overview
A Phase 2 trial of obeticholic acid in primary biliary cholangitis (PBC), sponsored by Intercept Pharmaceuticals. Started Oct 2019; status: terminated.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT04594694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04594694.